Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT03093155 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | completed | Phase 2 | 78 | Yale UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04823065 |
| 4FMFES-PET Imaging of Endometrial and Ovarian Cancers |
| completed |
| Phase 1 / Phase 2 |
| 53 |
| Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER |
| 1 |
| May 13, 2024 |
| clinicaltrials |
| NCT01439490 | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer | completed | Phase 2 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01088347 | Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 9 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03189446 | Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | completed | Phase 2 | 39 | University of OklahomaOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT01001910 | Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 22 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02766582 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | completed | Phase 2 | 29 | Medical College of WisconsinOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03936270 | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03476798 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium(Clovis-001) | completed | Phase 2 | 49 | University of OklahomaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03015129 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06226350 | A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | completed | Phase 2 | 29 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03117933 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer(OCTOVA) | completed | Phase 2 | 139 | University of OxfordOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04212377 | Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients(DECENDO) | completed | Phase 2 | 8 | Radboud University Medical CenterOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 140 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04590599 | A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | completed | Phase 2 | 205 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04284852 | Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting(NEOPRIMA) | completed | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | completed | Phase 2 | 52 | Nykode Therapeutics ASAINDUSTRY | 6 | Dec 15, 2023 | clinicaltrials |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 / Phase 2 | 88 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT03367923 | Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors | completed | Phase 2 | 47 | Stanford UniversityOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02567253 | Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer(OvIP1) | completed | Phase 2 | 56 | University Hospital, GhentOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT00112957 | Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT02744898 | A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus | completed | Phase 2 | 23 | NYU Langone HealthOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01357161 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | completed | Phase 2 | 136 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT01164995 | Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer(M10MKO) | completed | Phase 2 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT01397877 | GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer(ENDOPIK) | completed | Phase 2 | 24 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01583322 | Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer(CHIVA) | completed | Phase 2 | 188 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT01705158 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum(MYCA) | completed | Phase 1 / Phase 2 | 87 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02383251 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer(TAPAZ) | completed | Phase 2 | 118 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02584465 | REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression(REGOVAR) | completed | Phase 2 | 68 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04542356 | Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | completed | Phase 2 | 60 | Chongqing University Cancer HospitalOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT00993655 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | completed | Phase 2 | 275 | Canadian Cancer Trials GroupNETWORK | 4 | Aug 28, 2023 | clinicaltrials |
| NCT04590248 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma(ADAGIO) | completed | Phase 2 | 109 | AstraZenecaINDUSTRY | 5 | Aug 14, 2023 | clinicaltrials |
| NCT00053794 | Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00770185 | Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | completed | Phase 2 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04669002 | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | completed | Phase 2 | 34 | Ellipses PharmaINDUSTRY | 3 | Aug 2, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT05963334 | Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 49 | Cairo UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04417192 | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer(OLAPem) | completed | Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Jul 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2024source: clinicaltrials